Novo Nordisk to create 6000 jobs by 2022


Danish insulin and diabetes specialist Novo Nordisk says it intends to employ 6000 more highly skilled workers within Denmark by 2022. Half of these new staff will work in R&D. The announcement bucks the trend of recent years in pharma, which has tended to see companies downsizing drastically and closing R&D sites.

The company used its announcement to call on the Danish government to prioritise investment in research-based training in the sciences to ensure that research-driven Danish companies can continue to grow. ‘It will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent,’ said the firm’s chief science officer, Mads Krogsgaard Thomsen in a statement.


Related Content

Novo Nordisk quits inflammation R&D and cuts jobs

3 September 2014 Business

news image

Firm will return to primary focus on diabetes and obesity

$100m of diabetes R&D in China

24 September 2012 Business

news image

Novo Nordisk will create 130–200 new research jobs

Most Read

Magnetic resonance taken to the limit

21 November 2014 Research

news image

Technique can read the spin of a single nucleus opening up a new way to investigate proteins and complex molecules

Boron and beryllium finally shake hands

24 November 2014 Research

news image

Never-before-seen bond observed between periodic table neighbours

Most Commented

US approves low acrylamide spud

25 November 2014 News and Analysis

news image

The first genetically modified potato that produces less acrylamide has been granted approval in the US

Nanostripe controversy in new twist

24 November 2014 Research

news image

Creator of striped nanoparticles insists questions over structures have already been answered and accuses critics of a 'perso...